Proposed Data Collection Submitted for Public Comment and Recommendations, 60636-60638 [2024-16492]
Download as PDF
<![CDATA[
60636
Federal Register / Vol. 89, No. 144 / Friday, July 26, 2024 / Notices
Synthesis Screening—New—Office of
Science (OS), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
This data collection form was
developed pursuant to the Framework
for Nucleic Acid Synthesis Screening,
which was released by the Office of
Science and Technology Policy (OSTP)
in April of 2024. This framework was
directed by the Executive Order on the
Safe, Secure, and Trustworthy
Development of Artificial Intelligence,
and recommends that providers and
name, location, phone number and
email address to ensure there is a point
of contact with the company in case of
questions regarding compliance and
record keeping. This data is needed to
ensure the self-attestation form can be
filed and logged correctly, and to ensure
the government can reach out to the
correct contact if clarification if
necessary.
CDC requests OMB approval for an
estimated 20 annual burden hours.
There is no cost to respondents other
than their time to participate.
manufacturers of synthetic nucleic acids
screen their sequences and customers
before fulfilling orders to prevent
potential misuse.
The Attestation Form will collect
basic organizational information and an
attestation of compliance from providers
and manufacturers of synthetic nucleic
acids and benchtop nucleic acid
synthesis equipment. Data collected
includes organization name, location,
website, and type of organization. The
form also includes primary and
secondary contact information such as
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Providers and manufacturers of synthetic nucleic acids and bench top
nucleic acid synthesis equipment.
Total ...........................................
Annual Provider and Manufacturer
Self-Attestation Statement.
...........................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–16491 Filed 7–25–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled ‘‘Division of
Diabetes Translation Programmatic &
Participant User Experience Data
Collection’’ (DDTDC). This Generic
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
17:17 Jul 25, 2024
Jkt 262001
Fmt 4703
Total burden
(in hours)
20/60
20
........................
........................
........................
20
You may submit comments,
identified by Docket No. CDC–2024–
0057 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to www.regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
www.regulations.gov.
Please note: All public comment
should be submitted through the
Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
Frm 00038
Average
burden per
response
(in hours)
1
information collection, will enable
CDC’s Division of Diabetes Translation
(DDT) to collect data required in a
timely manner to support the
development, refinement, and
improvement of DDT’s education,
training, technical assistance (TA), and
communication/marketing activities.
DATES: CDC must receive written
comments on or before September 24,
2024.
PO 00000
Number of
responses per
respondent
60
ADDRESSES:
[60Day–24–24HQ; Docket No. CDC–2024–
00057]
VerDate Sep<11>2014
Number of
respondents
Form name
Sfmt 4703
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7118; Email: omb@
cdc.gov.
Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of the existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
SUPPLEMENTARY INFORMATION:
E:\FR\FM\26JYN1.SGM
26JYN1
Federal Register / Vol. 89, No. 144 / Friday, July 26, 2024 / Notices
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of collecting
information on those to respond,
including using appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic responses;
and
5. Assess information collection costs.
ddrumheller on DSK120RN23PROD with NOTICES1
Proposed Project
Division of Diabetes Translation
Programmatic & Participant User
Experience Data Collection (DDTDC)—
New—National Center for Chronic
Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Division of Diabetes Translation
(DDT) plays a crucial role in helping
prevent Type 2 diabetes, reducing
diabetes complications and disability,
and reducing diabetes-related
disparities across the United States.
DDT accomplishes this by providing
education, training, technical assistance
(TA), and engaging in communication/
marketing activities for various key
audiences. These customers include
national, state, and local partners,
grantees, providers (e.g., lifestyle
coaches, diabetes educators, healthcare
providers, health/medical and
community-based organizations), people
with prediabetes, diabetes and their
family, friends, and caregivers, and
other consumers of DDT products and
programs.
For DDT to be able to efficiently and
effectively do this work and fulfill its
mission, it needs to be able to collect
information and feedback from intended
audiences in a timely manner and with
enough frequency to ensure DDT can
deliver clear, effective, efficient, and
appropriate customer service. This
includes, for instance, collecting data on
key audiences’ needs, and on the reach,
uptake, use, customer experience and
satisfaction with DDT’s services,
products, and related programs,
including its education, training, TA
and communications services and
products. However, in the interest of
timely provision of services, DDT often
forgoes the important step of getting
input from its key audiences on the
clarity, efficiency, effectiveness, and
appropriateness of the services and
resources it develops and provides for
them. Skipping this information
collection step, or doing so with less
VerDate Sep<11>2014
17:17 Jul 25, 2024
Jkt 262001
frequency, avoids the delay involved in
the standard OMB review process
increases the risk of DDT wasting both
time and money developing and
providing education, training, TA, and
communication/marketing that will not
achieve the intended objectives and will
be unclear, irrelevant, or not fully meet
the needs of DDT’s audiences. It can
also have other unintended
consequences, such as jeopardizing the
credibility of Federal health officials.
The Division of Diabetes Translation
Programmatic & Participant User
Experience Data Collection (DDTDC)
will enable DDT to collect the
information they require in a timely
manner to:
• Provide clear, effective, efficient,
appropriate, and timely education,
communication, training, and technical
assistance to key audiences and other
interested groups, including consumer
audiences (e.g., people with prediabetes,
diabetes, and their family, friends, and
caregivers), providers (e.g., lifestyle
coaches, diabetes care and education
specialists, healthcare and other
providers, health/medical and
community-based organizations); and
partners (national, state, and local
partners).
• Ensure quality and prevent
duplication in the development and
dissemination of prevention and health
information and program activities by
DDT to consumers, providers, and state
and local partners.
• Conduct exploratory/formative
assessments to inform DDT’s
development of education,
communication/marketing, training, and
programmatic materials, tools, and
resources to support and improve the
prevention and management of diabetes.
For example, identifying key audiences’
knowledge, attitudes, behaviors,
motivators, and information needs.
• Assess the impact of programs,
messages, educational and training
materials among recipients and
determine to what extent they meet
relevant service-related DDT objectives
and goals.
The following are examples of the
areas of focus that the data collection
activities under this generic information
collection mechanism may include:
• Reach, uptake, use, customer
experience, and satisfaction with the
CDC-recognized lifestyle change
programs for Type 2 diabetes
prevention, as well as related outcomes
(e.g., participant retention and
recruitment rates).
• Satisfaction with CDC-recognized
lifestyle change programs toolkits, such
as the Personal Success Tool and
Champion toolkits.
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
60637
• Reach, uptake, use, customer
experience, and satisfaction with
diabetes education, type 2 prevention,
and diabetes management innovations
(such as the Diabetes Self-Management
Education and Support services
promotion initiative) and related shortterm effects on knowledge, awareness,
practices (such as information seeking),
and outcomes (such as enrollment of
people with diabetes or prediabetes).
• Reach, uptake, satisfaction,
customer experience, and short-term
outcomes of CDC’s training and
technical assistance resources (such as a
webinar or online toolkit).
• Needs assessments for customer
experience with, utilization of, and
short-term outcomes of technical
assistance and trainings for diabetes
prevention and management.
• Understandability, ease of use, and
appropriateness of diabetes education
messages, toolkits, programs, and
marketing materials.
• Exploratory assessments of
knowledge, attitudes, behaviors, beliefs,
barriers, and facilitators to uptake and
use of lifestyle change programs for
diabetes type 2 prevention and diabetes
management services and related
innovations, resources, tools, and
materials.
Data collection methods proposed
include, but are not limited to in-depth
individual interviews, cognitive
interviews, intercept interviews, groupbased discussions (including focus
groups and dyads/triads), surveys or
questionnaires, knowledge assessments,
observational assessments, and
implementation and utilization data
reporting. Respondents would include
key audiences and stakeholders of
CDC’s work, including representatives
of state and local DDT-funded
organizations; national, state, and local
DDT partners (not CDC-funded);
providers of type 2 diabetes prevention
and diabetes management programs and
services, including lifestyle coaches,
diabetes care and educations specialists,
healthcare and other providers; heath/
medical and community-based
organizations implementing programs
and services related to type 2 diabetes
prevention and diabetes management;
people with—and at risk for—diabetes
or with prediabetes; family, friends, and
caregivers of people with—and at risk
for—diabetes or with prediabetes.
As the methods for data collection
and audiences may vary with each
request submitted under this proposed
generic clearance, for each data
collection request unique instruments
(e.g., surveys, interview guides) will be
developed to address the specific topics
that information will be collected on.
E:\FR\FM\26JYN1.SGM
26JYN1
60638
Federal Register / Vol. 89, No. 144 / Friday, July 26, 2024 / Notices
The estimated annualized hourly
burden anticipated for all data
collection methods would total 2,000
hours and include eight to ten data
collection activities over the course of a
year. There is no cost to the respondents
other than their time.
ways to improve its services, products,
and programs to better meet its
audiences’ needs and achieve its
mission of supporting the prevention of
diabetes and reducing diabetes-related
complications and disparities across the
United States.
Questions to be asked may focus, for
example, on collecting data on the
audiences’ needs and on the reach,
uptake, use, customer experience and
satisfaction with DDT’s services,
products, and programs. Such
information will enable DDT to identify
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
Total burden
hours
Data collection methods
Representatives of state and local
DDT-funded organizations; National, State, and Local DDT partners; Providers of type 2 Diabetes
Prevention and Diabetes Management Programs and Services;
People, family, friends, and caregivers of people with—and at risk
for—Diabetes or with Prediabetes.
Interviews; Surveys or Questionnaires; Knowledge Assessments;
Motivation Assessments, Observational Assessments; Implementation and Utilization Data Reporting.
4,000
1
30/60
2,000
Total ...........................................
...........................................................
........................
........................
........................
2,000
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–16492 Filed 7–25–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–24–0212]
Agency Forms Undergoing Paperwork
Reduction Act Review
ddrumheller on DSK120RN23PROD with NOTICES1
Number of
responses per
respondent
Number of
respondents
Type of respondents
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘National
Hospital Care Survey (NHCS)’’ to the
Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on May 7, 2024 to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
VerDate Sep<11>2014
17:17 Jul 25, 2024
Jkt 262001
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies’ estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
comments within 30 days of notice
publication.
Proposed Project
National Hospital Care Survey
(NHCS) (OMB Control No. 0920–0212,
Exp. 12/31/2024)—Revision—National
Center for Health Statistics (NCHS),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Section 306 of the Public Health
Service (PHS) Act (42 U.S.C. 242k), as
amended, authorizes that the Secretary
of Health and Human Services (DHHS),
acting through NCHS, shall collect
statistics on the extent and nature of
illness and disability of the population
of the United States. This three-year
clearance request for National Hospital
Care Survey (NHCS) includes the
collection of all inpatient and
ambulatory Uniform Bill–04 (UB–04)
claims data or electronic health record
(EHR) data as well as the collection of
hospital-level information via a
questionnaire from a sample of 601
hospitals.
The National Ambulatory Medical
Care Survey (NAMCS) was conducted
intermittently from 1973 through 1985,
and annually since 1989. The survey is
conducted under authority of Section
306 of the Public Health Service Act (42
U.S.C. 242k). The National Hospital
Discharge Survey (NHDS) (OMB No.
0920–0212, Exp. Date 01/31/2019),
conducted continuously between 1965
and 2010, was the Nation’s principal
source of data on inpatient utilization of
short-stay, non-institutional, nonFederal hospitals, and was the principal
E:\FR\FM\26JYN1.SGM
26JYN1
]]>Agencies
[Federal Register Volume 89, Number 144 (Friday, July 26, 2024)]
[Notices]
[Pages 60636-60638]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16492]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-24HQ; Docket No. CDC-2024-00057]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on a proposed information collection project
titled ``Division of Diabetes Translation Programmatic & Participant
User Experience Data Collection'' (DDTDC). This Generic information
collection, will enable CDC's Division of Diabetes Translation (DDT) to
collect data required in a timely manner to support the development,
refinement, and improvement of DDT's education, training, technical
assistance (TA), and communication/marketing activities.
DATES: CDC must receive written comments on or before September 24,
2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0057 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. All relevant comments received will be posted
without change to www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to www.regulations.gov.
Please note: All public comment should be submitted through the
Federal eRulemaking portal (www.regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7118;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of the existing collection
of information, and each reinstatement of previously approved
information collection before submitting the collection to the OMB for
approval. To comply with this requirement, we are publishing this
notice of a proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information,
[[Page 60637]]
including the validity of the methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of collecting information on those to
respond, including using appropriate automated, electronic, mechanical,
or other technological collection techniques or other forms of
information technology, e.g., permitting electronic responses; and
5. Assess information collection costs.
Proposed Project
Division of Diabetes Translation Programmatic & Participant User
Experience Data Collection (DDTDC)--New--National Center for Chronic
Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The Division of Diabetes Translation (DDT) plays a crucial role in
helping prevent Type 2 diabetes, reducing diabetes complications and
disability, and reducing diabetes-related disparities across the United
States. DDT accomplishes this by providing education, training,
technical assistance (TA), and engaging in communication/marketing
activities for various key audiences. These customers include national,
state, and local partners, grantees, providers (e.g., lifestyle
coaches, diabetes educators, healthcare providers, health/medical and
community-based organizations), people with prediabetes, diabetes and
their family, friends, and caregivers, and other consumers of DDT
products and programs.
For DDT to be able to efficiently and effectively do this work and
fulfill its mission, it needs to be able to collect information and
feedback from intended audiences in a timely manner and with enough
frequency to ensure DDT can deliver clear, effective, efficient, and
appropriate customer service. This includes, for instance, collecting
data on key audiences' needs, and on the reach, uptake, use, customer
experience and satisfaction with DDT's services, products, and related
programs, including its education, training, TA and communications
services and products. However, in the interest of timely provision of
services, DDT often forgoes the important step of getting input from
its key audiences on the clarity, efficiency, effectiveness, and
appropriateness of the services and resources it develops and provides
for them. Skipping this information collection step, or doing so with
less frequency, avoids the delay involved in the standard OMB review
process increases the risk of DDT wasting both time and money
developing and providing education, training, TA, and communication/
marketing that will not achieve the intended objectives and will be
unclear, irrelevant, or not fully meet the needs of DDT's audiences. It
can also have other unintended consequences, such as jeopardizing the
credibility of Federal health officials.
The Division of Diabetes Translation Programmatic & Participant
User Experience Data Collection (DDTDC) will enable DDT to collect the
information they require in a timely manner to:
Provide clear, effective, efficient, appropriate, and
timely education, communication, training, and technical assistance to
key audiences and other interested groups, including consumer audiences
(e.g., people with prediabetes, diabetes, and their family, friends,
and caregivers), providers (e.g., lifestyle coaches, diabetes care and
education specialists, healthcare and other providers, health/medical
and community-based organizations); and partners (national, state, and
local partners).
Ensure quality and prevent duplication in the development
and dissemination of prevention and health information and program
activities by DDT to consumers, providers, and state and local
partners.
Conduct exploratory/formative assessments to inform DDT's
development of education, communication/marketing, training, and
programmatic materials, tools, and resources to support and improve the
prevention and management of diabetes. For example, identifying key
audiences' knowledge, attitudes, behaviors, motivators, and information
needs.
Assess the impact of programs, messages, educational and
training materials among recipients and determine to what extent they
meet relevant service-related DDT objectives and goals.
The following are examples of the areas of focus that the data
collection activities under this generic information collection
mechanism may include:
Reach, uptake, use, customer experience, and satisfaction
with the CDC-recognized lifestyle change programs for Type 2 diabetes
prevention, as well as related outcomes (e.g., participant retention
and recruitment rates).
Satisfaction with CDC-recognized lifestyle change programs
toolkits, such as the Personal Success Tool and Champion toolkits.
Reach, uptake, use, customer experience, and satisfaction
with diabetes education, type 2 prevention, and diabetes management
innovations (such as the Diabetes Self-Management Education and Support
services promotion initiative) and related short-term effects on
knowledge, awareness, practices (such as information seeking), and
outcomes (such as enrollment of people with diabetes or prediabetes).
Reach, uptake, satisfaction, customer experience, and
short-term outcomes of CDC's training and technical assistance
resources (such as a webinar or online toolkit).
Needs assessments for customer experience with,
utilization of, and short-term outcomes of technical assistance and
trainings for diabetes prevention and management.
Understandability, ease of use, and appropriateness of
diabetes education messages, toolkits, programs, and marketing
materials.
Exploratory assessments of knowledge, attitudes,
behaviors, beliefs, barriers, and facilitators to uptake and use of
lifestyle change programs for diabetes type 2 prevention and diabetes
management services and related innovations, resources, tools, and
materials.
Data collection methods proposed include, but are not limited to
in-depth individual interviews, cognitive interviews, intercept
interviews, group-based discussions (including focus groups and dyads/
triads), surveys or questionnaires, knowledge assessments,
observational assessments, and implementation and utilization data
reporting. Respondents would include key audiences and stakeholders of
CDC's work, including representatives of state and local DDT-funded
organizations; national, state, and local DDT partners (not CDC-
funded); providers of type 2 diabetes prevention and diabetes
management programs and services, including lifestyle coaches, diabetes
care and educations specialists, healthcare and other providers; heath/
medical and community-based organizations implementing programs and
services related to type 2 diabetes prevention and diabetes management;
people with--and at risk for--diabetes or with prediabetes; family,
friends, and caregivers of people with--and at risk for--diabetes or
with prediabetes.
As the methods for data collection and audiences may vary with each
request submitted under this proposed generic clearance, for each data
collection request unique instruments (e.g., surveys, interview guides)
will be developed to address the specific topics that information will
be collected on.
[[Page 60638]]
Questions to be asked may focus, for example, on collecting data on the
audiences' needs and on the reach, uptake, use, customer experience and
satisfaction with DDT's services, products, and programs. Such
information will enable DDT to identify ways to improve its services,
products, and programs to better meet its audiences' needs and achieve
its mission of supporting the prevention of diabetes and reducing
diabetes-related complications and disparities across the United
States.
The estimated annualized hourly burden anticipated for all data
collection methods would total 2,000 hours and include eight to ten
data collection activities over the course of a year. There is no cost
to the respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of
Type of respondents Data collection Number of responses per Average burden Total burden
methods respondents respondent per response hours
----------------------------------------------------------------------------------------------------------------
Representatives of state and Interviews; 4,000 1 30/60 2,000
local DDT-funded Surveys or
organizations; National, Questionnaires;
State, and Local DDT Knowledge
partners; Providers of type 2 Assessments;
Diabetes Prevention and Motivation
Diabetes Management Programs Assessments,
and Services; People, family, Observational
friends, and caregivers of Assessments;
people with--and at risk for-- Implementation
Diabetes or with Prediabetes. and Utilization
Data Reporting.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 2,000
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-16492 Filed 7-25-24; 8:45 am]
BILLING CODE 4163-18-P
